6:15 PM
Jun 11, 2009
 |  BC Extra  |  Clinical News

LB03002 meets growth hormone deficiency endpoint

Bioton S.A. (Warsaw, Poland) and LG Life Sciences Ltd. (KSE:068870) said a double-blind, European and U.S. Phase III...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >